P
CABA icon

&Partners’s Cabaletta Bio CABA Stock Holding History

&Partners’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4K Buy
+16,200
New +$53.3K ﹤0.01% 2490

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

&Partners's CABA Position: Q2 2026 in Review

&Partners opened a new position in Cabaletta Bio (CABA) in Q2 2026: 16,200 shares worth $50.4K. The stake represents ﹤0.01% of the portfolio and ranks #2490 among its holdings.

140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • &Partners held 16,200 shares of Cabaletta Bio worth $50.4K as of Q2 2026.
  • Cabaletta Bio was a new &Partners position in Q2 2026.
  • Cabaletta Bio made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2490 holding.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.